OCON Healthcare

Key People

• Keren Leshem - CEO
• Dr. Anula Jayasuriya - Chairwoman
• Prof. Sergio Haimovich, MD, PhD - Chief Medical Officer
• Adely Levy - VP RA/QA
• Daniel Sclar - VP Operations
• Rachel Safra-Zafrany - Director Clinical Operations
• Susan Alpert, PhD, MD - Senior Regulatory Advisor

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical technology and regulatory affairs.

The leadership includes individuals like CEO Keren Leshem and Chairwoman Dr. Anula Jayasuriya, who bring substantial expertise in MedTech and investment, respectively. Their combined experience enhances the company's strategic direction and operational execution.

Clinical Need

Aspect: Very Strong
Summary: OCON Healthcare addresses significant unmet needs in women's health, particularly in treating abnormal uterine bleeding and providing hormone-free contraceptive options.

Abnormal uterine bleeding affects approximately 15% of the global female population, highlighting a substantial need for effective treatments. OCON's products, such as the IUB SEAD and IUB PRIMA, aim to provide innovative solutions for these conditions.

Competition

Aspect: Somewhat crowded
Summary: The market for intrauterine devices and treatments for uterine pathologies includes several established players, but OCON's unique 3D drug delivery system offers differentiation.

Traditional intrauterine devices are predominantly T-shaped, whereas OCON's spherical design aims to reduce irritation and improve comfort. This innovation may attract users seeking alternatives to existing options.

Technical Challenge

Aspect: Predictable
Summary: The development of OCON's products involves established medical device technologies, suggesting manageable technical challenges.

OCON's IUB platform utilizes a 3D stent drug delivery frame, a concept grounded in existing medical device engineering principles. This predictability facilitates smoother development and regulatory approval processes.

Patent

Aspect: Very Strong
Summary: OCON holds a robust patent portfolio, providing significant protection for its innovative technologies.

With a total of 39 patents, OCON has secured comprehensive intellectual property rights for its products, including the IUB Ballerine and other pipeline devices. This extensive patent coverage safeguards against competitors and supports long-term market positioning.

Financing

Aspect: Well-funded
Summary: OCON has successfully secured substantial funding from reputable investors, indicating strong financial health.

The funding round led by RH Capital, with participation from Features Capital, Astia Angels, and others, reflects investor confidence in OCON's business model and growth prospects. These funds are earmarked for advancing clinical programs and expanding the product portfolio.

Regulatory

Aspect: 510k/PMA
Summary: OCON's products have obtained regulatory approvals in multiple countries, facilitating market entry.

The IUB Ballerine is commercially available in 30 countries, demonstrating successful navigation of various regulatory environments. OCON continues to pursue additional approvals to expand its global footprint.

Opportunity Rollup

Odds of Success

3.8

Peak Market Share

4.85

Segment CAGR

4.6%

Market Segment

Reproductive Health Devices

Market Sub Segment

Intrauterine Devices

Key Takeaway

OCON Healthcare's innovative IUB platform addresses significant unmet needs in women's health, supported by a strong team and robust patent portfolio, positioning the company for substantial growth in the reproductive health device market.